Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Accumulated Expenses (2017 - 2021)

Cogent Biosciences has reported Accumulated Expenses over the past 5 years, most recently at $2.1 million for Q3 2021.

  • Quarterly results put Accumulated Expenses at $2.1 million for Q3 2021, down 62.89% from a year ago — trailing twelve months through Sep 2021 was $2.1 million (down 62.89% YoY), and the annual figure for FY2020 was $4.8 million, down 32.98%.
  • Accumulated Expenses for Q3 2021 was $2.1 million at Cogent Biosciences, up from $1.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for COGT hit a ceiling of $8.2 million in Q1 2021 and a floor of $357000.0 in Q1 2018.
  • Median Accumulated Expenses over the past 5 years was $5.5 million (2018), compared with a mean of $4.4 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 1599.44% in 2019 and later tumbled 77.57% in 2021.
  • Cogent Biosciences' Accumulated Expenses stood at $3.0 million in 2017, then soared by 85.47% to $5.5 million in 2018, then surged by 30.2% to $7.1 million in 2019, then tumbled by 32.98% to $4.8 million in 2020, then crashed by 57.02% to $2.1 million in 2021.
  • The last three reported values for Accumulated Expenses were $2.1 million (Q3 2021), $1.3 million (Q2 2021), and $8.2 million (Q1 2021) per Business Quant data.